RxDoctor Payments Data

Sangeeta Mandapaka, MD

Interventional Cardiology · Charleston, WVNPI 1932309291

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,854 of the $4,626 with a category attached, or 61.7%. 11 manufacturers reported payments, led by Abbott at 42.5% of the total. Reporting peaked in 2024 at $3,481 and has fallen 91.3% since, to $304 in 2025. That places this record below the midpoint for interventional cardiology clinicians in WV, where the typical reported total is $7,222.

$4,626in general payments, 2019–2025

Across 104 payments — averaging $44.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$807
  • Boston Scientific$752
  • Shockwave Medical, Inc$706
  • Teleflex LLC$134
  • Abiomed$95
  • plus $167 from 5 others

What the payments were for

  • Travel & lodging$1,77238%
  • Food & beverage$2,85462%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,626 in reported general payments places this provider in the 40th percentile of 46 interventional cardiology providers in West Virginia.

See all interventional cardiology providers in West Virginia

Medicare billing

Part B allowed, 2024
$251,683
Medicare patients
2,535
Services billed
4,921

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BrilintaTicagrelor231$173,752
EliquisApixaban115$140,014
Repatha SureclickEvolocumab73$90,552
EntrestoSacubitril/Valsartan52$85,752
Repatha SyringeEvolocumab18$23,365
Ranolazine ErRanolazine219$12,973
Nebivolol Hcl174$6,136
Metoprolol Succinate242$3,738
Prasugrel Hcl69$3,556
Ezetimibe210$3,331
Isosorbide Mononitrate ErIsosorbide Mononitrate245$2,857
Isosorbide Mononitrate64$2,848
Atorvastatin Calcium299$2,462
Rosuvastatin Calcium285$2,456
Amiodarone Hcl97$1,650

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$22$85,75252 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 46 interventional cardiology providers in West Virginia.

Other interventional cardiology in Charleston

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →